Acta Pharmacologica Sinica, Published online: 10 November 2026; doi:10.1038/s41401-026-01945-z Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren’s disease
Wen-jie Liang, Hui-min Zou, Xin-yue Chen, Xu-meng Fu, Jie Wang, Feriel Rebhi et al. Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren’s disease. // Acta Pharmacologica Sinica. – 2026. – DOI: 10.1038/s41401-026-01945-z. – URL: https://www.nature.com/articles/s41401-026-01945-z
Wen-jie Liang, Hui-min Zou, Xin-yue Chen, Xu-meng Fu, Jie Wang, Feriel Rebhi, Gaetane Nocturne, Xavier Mariette, Li-long Pan, Julien Diana, & Jia Sun (2026). Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren’s disease. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-026-01945-z
Wen-jie Liang, et al. “Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren’s disease.” Acta Pharmacologica Sinica, 2026. doi:10.1038/s41401-026-01945-z.
@article{Liang2026,
title = {Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren’s disease},
author = {Liang, Wen-jie and Zou, Hui-min and Chen, Xin-yue and Fu, Xu-meng and Wang, Jie and Rebhi, Feriel and Nocturne, Gaetane and Mariette, Xavier and Pan, Li-long and Diana, Julien and Sun, Jia},
journal = {Acta Pharmacologica Sinica},
year = {2026},
doi = {10.1038/s41401-026-01945-z},
url = {https://www.nature.com/articles/s41401-026-01945-z}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...